When and How Long to Treat Chronic Lymphocytic Leukemia?

Q1 Medicine
Carsten U Niemann, Abraham Varghese, Talha Munir, Ellinor Goergen, Barbara Eichhorst
{"title":"When and How Long to Treat Chronic Lymphocytic Leukemia?","authors":"Carsten U Niemann, Abraham Varghese, Talha Munir, Ellinor Goergen, Barbara Eichhorst","doi":"10.1200/EDBK-25-473656","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment initiation follows the Rai and Binet staging systems, but the International Workshop on Chronic Lymphocytic Leukemia criteria emphasize active disease rather than stage alone. Early treatment in asymptomatic, high-risk patients has not shown an overall survival benefit, even with targeted therapies such as Bruton's tyrosine kinase and BCL2 inhibitors. The watch-and-wait strategy remains standard, although future trials may refine early treatment indications for specific high-risk groups.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473656"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/EDBK-25-473656","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment initiation follows the Rai and Binet staging systems, but the International Workshop on Chronic Lymphocytic Leukemia criteria emphasize active disease rather than stage alone. Early treatment in asymptomatic, high-risk patients has not shown an overall survival benefit, even with targeted therapies such as Bruton's tyrosine kinase and BCL2 inhibitors. The watch-and-wait strategy remains standard, although future trials may refine early treatment indications for specific high-risk groups.

慢性淋巴细胞白血病何时治疗,需要多长时间?
慢性淋巴细胞白血病(CLL)仍然是一种无法治愈的疾病,除非在极少数情况下用同种异体干细胞移植治疗或用化学免疫疗法治疗有利风险的CLL。治疗开始遵循Rai和Binet分期系统,但慢性淋巴细胞白血病国际研讨会的标准强调活动性疾病,而不是单独分期。无症状高风险患者的早期治疗并未显示出总体生存获益,即使采用靶向治疗,如布鲁顿酪氨酸激酶和BCL2抑制剂。观察和等待策略仍然是标准的,尽管未来的试验可能会细化针对特定高危人群的早期治疗适应症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
期刊介绍: The Ed Book is a National Library of Medicine–indexed collection of articles written by ASCO Annual Meeting faculty and invited leaders in oncology. Ed Book was launched in 1985 to highlight standards of care and inspire future therapeutic possibilities in oncology. Published annually, each volume highlights the most compelling research and developments across the multidisciplinary fields of oncology and serves as an enduring scholarly resource for all members of the cancer care team long after the Meeting concludes. These articles address issues in the following areas, among others: Immuno-oncology, Surgical, radiation, and medical oncology, Clinical informatics and quality of care, Global health, Survivorship.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信